BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Scil Proteins GmbH Establishes Business Development Infrastructure in North America


3/14/2012 9:30:48 AM

Halle, Germany, 14th March 2012- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, today announced that it has established a California-based Business Development organization in direct response to the ever-increasing demand for the Company’s protein production services in North America. The organization will provide local business support for the Company’s US and Canadian CMO customers.

Scil Proteins is delighted to announce that it has appointed Garry Merry to lead this new organization. Mr. Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies GmbH, Isogenica Ltd. and TerraSep LLC. Mr. Merry has also held senior executive positions at several leading life science companies, including Waters, Applied Biosystems and Qiagen.

“A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,” said Frank Ubags, COO of Scil Proteins. “With his background in protein engineering and separations, Garry Merry is ideally positioned to help us achieve our growth objectives.”

Commenting on his appointment, Garry Merry added, “My career has always revolved around proteins, going back as far back as 1986, when I helped found the Protein Society. That being said, I am pleased that Scil Proteins has asked me to support their business efforts here in North America and I am confident that the Company’s world-class GMP facility in Germany will be extremely busy going forward.”

Scil Proteins’ powerful Affilin® drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the Company’s corporate headquarter in Halle, Germany. In addition, Scil Proteins’ corporate headquarters will remain responsible for all other activities related to the Company’s CMO business outside of the US and Canada.

About Scil Proteins

Scil Proteins is a biopharmaceutical company working with industry partners in the development and manufacture of protein therapeutics and diagnostics as well as discovering and developing proprietary Affilin® molecules. The Company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment and a particular expertise at refolding proteins, Scil Proteins has an excellent track record in supplying a top level support for its partners. Scil Proteins has supported a number of different companies in process development and biomanufacturing. Scil Proteins also has a discovery platform that is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer. Scil Proteins is a well-established private company located in Halle, Germany.

To learn more about Scil Proteins, please visit www.scilproteins.com.

Contacts:

Scil Proteins GmbH

Ulrike Fiedler

CEO

t: +49 (0) 345 27 99 63 61

e: ulrike.fiedler@scilproteins.com

College Hill

Lauren McConville

Account Manager

t: (Germany) +49 (0) 89 52 05 92 12

e: scilproteins@collegehill.com

Scil Proteins North America

Garry Merry

Business Development Consultant

t: +1 510 846 0736

e:garry.merry@scilproteins.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES